NCT02379416: Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

NCT02379416
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 12 Years to 120 Years (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active brain metastases or leptomeningeal disease – see trial for details
https://ClinicalTrials.gov/show/NCT02379416

Comments are closed.

Up ↑